A. B. FERHANOĞLU Et Al. , "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience," American society of Hematology Congress , vol.130, atlanta, United States Of America, pp.5173, 2017
FERHANOĞLU, A. B. Et Al. 2017. Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience. American society of Hematology Congress , (atlanta, United States Of America), 5173.
FERHANOĞLU, A. B., ÖZBALAK, M., SALİHOĞLU, a., SOYSAL, T., KARADOĞAN, İ., PAYDAŞ, S., ... ÖZDEMİR, E.(2017). Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience . American society of Hematology Congress (pp.5173). atlanta, United States Of America
FERHANOĞLU, AHMET Et Al. "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience," American society of Hematology Congress, atlanta, United States Of America, 2017
FERHANOĞLU, AHMET B. Et Al. "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience." American society of Hematology Congress , atlanta, United States Of America, pp.5173, 2017
FERHANOĞLU, A. B. Et Al. (2017) . "Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience." American society of Hematology Congress , atlanta, United States Of America, p.5173.
@conferencepaper{conferencepaper, author={AHMET BURHAN FERHANOĞLU Et Al. }, title={Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience}, congress name={American society of Hematology Congress}, city={atlanta}, country={United States Of America}, year={2017}, pages={5173} }